

Sheet 1 of 2

R88 1 5 2002 FORM PTO-14

U.S. DEPARTMENT OF COMMERCE RATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: AL01019 SERIAL NO.: 09/955,383

INF	INFORMATION SCLOSURE STATEMENT					AL01019		09/955,383		
	ORN	AAMOONSCLOS BY APPLIC	SURE ST CANT	ATEMENT	APPLICANT: ASLANIAN				,	
(Use several sheets if necess				sary)	FILING DATE: Sept. 18, 20		GROUP: 1642			
			U.S. F	ATENT DOCUM			<u> </u>			
EXAMINEI INITIAL	R	DOCUMENT NUMBER	DATE	NAM		CLASS	Skip	FILING	DATE I	
itiu	AA	4,767,778	8/88	U.S. PATENT	·	514	243	APPRO	PRIATE	
H.C.	AB	5,352,707	10/94	U.S. PATENT		2514	Aci			
H.C.	AC	5,869,479	2/99	U.S. PATENT		199	138	(),	`	
	AD					1/2	7720	6	À	
	AE					S	CA C	5.	\ \	
····	AF				4-		99,	105		
			FOREIGN	N PATENT DOC	LIMENTS	.k	000			
	T	DOCUMENT	DATE	COUNTRY	OMENIS	CLACC	CUD	200		
	1 .	NUMBER		COUNTRY		CLASS	SUB- *	BANS	LATION	
11.6.	AG	WO 93/01812	2/93	INTERNATIONAL	DATENT	-	CLASS.	YES	NO	
HLI	AH	WO 93/12093	6/93	INTERNATIONAL		 		 	 	
Ja.L.	AI	WO 95/14007	5/95	INTERNATIONAL		 			 	
H.C.	AJ	WO 98/58646	12/98	INTERNATIONAL				 	┼	
11.6.	AK	WO 96/29315	9/96	INTERNATIONAL					 -	
j-1.L 1	AL	EU 0448 765 B1	3/90	EUROPEAN PAT						
Hills	AM	EU 0 420 396 B1	7/90	EUROPEAN PAT					 	
·	AN		17.00	LONG! LANT AT					 	
	AO								-	
	OTI	JED DOCLINATION	C (In alves	line A. H Title	5 (5 (·			L	
	AP	HER DOCUMENT	S (includ	ing Author, Title	, Date, Perti	nent Pa	ges, Etc	c.)		
H.L.	^	Howson, Bioorganic H3 Receptor Agonis	& Medicina to Vol 3 m	31 Chemistry Letters	, Two Novel, F	otent and	Selective	e Histan	nine	
	AQ	Stark J Med Chem	Novel C	p. 77-78, 1992. arbamatos as Beter	at Historias II	2 Danasta	A A			
A.C.		Stark, J. Med. Chem., Novel Carbamates as Potent Histamine H3 Receptor Antagonists with High in Vitro and Oral In Vivo Activity, 39, pp. 1157-1163.								
1. 1 .	1	Sasse, Bioorganic & Medicinal Chemistry , (Partial) Agonist/Antagonist Properties of Novel								
4. 1 .	IAR I	Sasse, Bioorganic &	Medicinal	ctivity, 39, pp. 1157 Chemistry (Partial)	-1163.		nortice of			
1KC	AR	Sasse, Bioorganic &	Medicinal	Chemistry , (Partial)	-1163.		perties of			
Hr.	AS	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20 Bagley, J. Med. Cher	Medicinal 00) pp. 113	Chemistry , (Partial) 39-1149.	-1163.) Agonist/Antaç	jonist Proj		Novel		
		Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M	Medicinal 00) pp. 113 m. 1991, N	Chemistry , (Partial) 39-1149. ew 1-(Heterocyclyla nemistry Letters, Dir	-1163.) Agonist/Antaç alkyl)-4-(Propio	onist Prop nanilido)-4	4-Piperidi	Novel	pp	
Hr.	AŞ	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20	Medicinal 00) pp. 113 m. 1991, N ledicinal Cl 013-2018, 1	Chemistry , (Partial) 39-1149. ew 1-(Heterocyclyla nemistry Letters, Dig 1996.	-1163.) Agonist/Antag alkyl)-4-(Propio ohenylmethyl E	ponist Prop nanilido)- thers: Syr	4-Piperidi nthesis a	Novel inyl, 34, nd Hista	pp ımine,	
trr.	AS AT	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. C 1963-1970, 1989.	Medicinal 00) pp. 113 m. 1991, N ledicinal Cl 013-2018, 1 Chem. 198	Chemistry, (Partial) 39-1149. ew 1-(Heterocyclylanemistry Letters, Dig 1996. 9, Synthesis and in	-1163.) Agonist/Antagolikyl)-4-(Propio ohenylmethyl E Vitro Pharmac	nanilido)- thers: Syr	4-Piperidi nthesis a	Novel nyl, 34, nd Hista ne, 32, p	pp mine,	
H.C.	AS AT	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. C 1963-1970, 1989.	Medicinal 00) pp. 113 m. 1991, N ledicinal Cl 013-2018, 1 Chem. 198	Chemistry, (Partial) 39-1149. ew 1-(Heterocyclylanemistry Letters, Dig 1996. 9, Synthesis and in	-1163.) Agonist/Antagolikyl)-4-(Propio ohenylmethyl E Vitro Pharmac	nanilido)- thers: Syr	4-Piperidi nthesis a	Novel nyl, 34, nd Hista ne, 32, p	pp mine,	
Hr.F.	AS AT AU	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. 0 1963-1970, 1989. Schulze, Arch. Pharm pp. 455-462, 1994.	Medicinal 00) pp. 113 m. 1991, N ledicinal Cl 013-2018, 1 Chem. 1989 n. (Weinhe	Chemistry, (Partial) 39-1149. ew 1-(Heterocyclyla nemistry Letters, Dig 1996. 9, Synthesis and in im), Synthese und k	-1163.) Agonist/Antag	nanilido)- thers: Syrology of A /H2-antag	4-Piperidi nthesis a rpromidir onistisch	Novel nyl, 34, nd Hista ne, 32, p	pp imine, p	
H.C.	AS, AT AU	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. 0 1963-1970, 1989. Schulze, Arch. Pharm pp. 455-462, 1994 Schulze, European J.	Medicinal 00) pp. 113 m. 1991, N ledicinal Cl 013-2018, 1 Chem. 1989 n. (Weinhe	Chemistry, (Partial) 39-1149. ew 1-(Heterocyclyla nemistry Letters, Dig 1996. 9, Synthesis and in im), Synthese und k harmaceutical Scie	-1163.) Agonist/Antag	nanilido)- thers: Syrology of A /H2-antag	4-Piperidi nthesis a rpromidir onistisch	Novel nyl, 34, nd Hista ne, 32, p	pp Imine, p	
#(C) #(C) #(C)	AS AT AU AV	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. 0 1963-1970, 1989. Schulze, Arch. Pharm pp. 455-462, 1994 Schulze, European Jantagonists, Vol 6, pp. van der Goot, Eur J.	Medicinal (00) pp. 113 m. 1991, N ledicinal Cl (13-2018, 1 Chem. 1989 n. (Weinhe ournal of Po. 177-186,	Chemistry , (Partial) 39-1149. ew 1-(Heterocyclylanemistry Letters, Dip 1996. 9, Synthesis and in im), Synthese und k harmaceutical Scien 1998.	-1163.) Agonist/Antagalkyl)-4-(Propio phenylmethyl E Vitro Pharmac combinierte H1 nces, Combine	nanilido)- thers: Syn ology of A /H2-antag	4-Piperidinthesis and rpromidir conistische H1/H2	Novel nyl, 34, nd Hista ne, 32, p e, Vol. 3	pp mine, p 327,	
H.C. H.C. H.C.	AS AT AU AV	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. 0 1963-1970, 1989. Schulze, Arch. Pharm pp. 455-462, 1994 Schulze, European J. antagonists, Vol 6, pp. van der Goot, Eur J. pp. 511-517, 1992.	Medicinal (00) pp. 113m. 1991, No. 1991, No. 1991, No. 1991, No. 1991, 100, 100, 100, 100, 100, 100, 100	Chemistry , (Partial) 39-1149. ew 1-(Heterocyclylatemistry Letters, Dig. 1996. 9, Synthesis and in im), Synthese und kermaceutical Scientings. 1998. 1. , Isothiourea analysis	-1163.) Agonist/Antagalkyl)-4-(Propio phenylmethyl E Vitro Pharmac combinierte H1 nces, Combine ogues of histar	nanilido)- thers: Syn plogy of A /H2-antag d histamir mine as po	4-Piperidinthesis and rpromidir conistische H1/H2 otent ago	Novel nyl, 34, nd Hista ne, 32, p e, Vol. 3 recepto	pp mine, p 327,	
# (. # (. # (. # (.	AV AW	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. 0 1963-1970, 1989. Schulze, Arch. Pharm pp. 455-462, 1994 Schulze, European J. antagonists, Vol 6, pp. van der Goot, Eur J. pp. 511-517, 1992. Walczynski, II Farmac	Medicinal 00) pp. 113 m. 1991, N ledicinal Cl 013-2018, 1 Chem. 1989 n. (Weinhe ournal of P o. 177-186, Med. Chen co, Non-im	Chemistry, (Partial) 39-1149. ew 1-(Heterocyclylatemistry Letters, Dip 1996. 9, Synthesis and in im), Synthese und k harmaceutical Scienting 1998. n., Isothiourea analidazole histamine H	-1163.) Agonist/Antagolist/Antag	nanilido) - ithers: Syr plogy of A /H2-antag d histamir mine as po	4-Piperidinthesis and rpromidir conistisch me H1/H2 otent ago	Novel nyl, 34, nd Hista ne, 32, p e, Vol. 3 recepto nists, Vo	pp mine, p 327, or	
# (. # (. # (. # (. # (. # (.	AS AT AU AV AW AX AY AZ	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. C 1963-1970, 1989. Schulze, Arch. Pharm pp. 455-462, 1994 Schulze, European Jantagonists, Vol 6, pp. van der Goot, Eur J. pp. 511-517, 1992. Walczynski, II Farmar Brown, Br. J. Pharmar West, Molecular Pharmar	Medicinal 00) pp. 113 m. 1991, N ledicinal Cl 013-2018, 1 Chem. 1989 n. (Weinhe ournal of P p. 177-186, Med. Chen co, Non-imac., Pharm	Chemistry , (Partial) 39-1149. ew 1-(Heterocyclylatemistry Letters, Dip 1996. 9, Synthesis and in im), Synthese und k harmaceutical Scien 1998. h. , Isothiourea anal idazole histamine H acological studies w	-1163.) Agonist/Antagolist/Antag	nanilido) - ithers: Syr plogy of A /H2-antag d histamir mine as po	4-Piperidinthesis and rpromidir nonistisch ne H1/H2 ptent ago	Novel nyl, 34, nd Hista ne, 32, p e, Vol. 3 recepto nists, Vo.	pp mine, p 327, or ol 27,	
# (· # (· # (· # (· # (·	AV AW AX AY AZ	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. C 1963-1970, 1989. Schulze, Arch. Pharm pp. 455-462, 1994 Schulze, European Jantagonists, Vol 6, pp. van der Goot, Eur J. pp. 511-517, 1992. Walczynski, II Farmar Brown, Br. J. Pharmar West, Molecular Pharpp. 610-613, 1990.	Medicinal (00) pp. 113 m. 1991, N ledicinal Cl (113-2018, 1 Chem. 1989 n. (Weinher ournal of Po. 177-186, Med. Chem. (113-2018) m. (Non-imac., Pharmacology,	Chemistry , (Partial) 39-1149. ew 1-(Heterocyclylater) 1996. 9, Synthesis and in im), Synthese und kermaceutical Scientings. 1998. 1. , Isothiourea analytical sudies we dentificatin of Two	-1163.) Agonist/Antagolist/Antag	nanilido)- ithers: Syr plogy of A /H2-antag d histamir mine as po 54, pp. 68 144, Vol. 8 Receptor	4-Piperidinthesis and rpromidir nonistisch ne H1/H2 otent ago 14-694, 197, pp. 56 Subtype	nyl, 34, and Hista ne, 32, p e, Vol. 3 recepto nists, Vo 999. 9-578, s, Vol. 3	pp mine, p 327, or ol 27, 1986.	
# (. # (. # (. # (. # (. # (. # (. # (. # (.	AV AW AX AY AZ BA	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. (1963-1970, 1989. Schulze, Arch. Pharm pp. 455-462, 1994 Schulze, European Jantagonists, Vol 6, pp. van der Goot, Eur J. pp. 511-517, 1992. Walczynski, II Farmar Brown, Br. J. Pharma West, Molecular Pharpp. 610-613, 1990. Clapham, Brit. J. Pha	Medicinal 00) pp. 113 m. 1991, N ledicinal Cl 013-2018, 1 Chem. 1989 n. (Weinhe ournal of P o. 177-186, Med. Chen co, Non-im macology, rm. Suppl.	Chemistry , (Partial) 39-1149. ew 1-(Heterocyclylater) 1996. 9, Synthesis and in im), Synthese und kermaceutical Scientings. 1998. 1. , Isothiourea analytical sudies we dentificatin of Two	-1163.) Agonist/Antagolist/Antag	nanilido)- ithers: Syr plogy of A /H2-antag d histamir mine as po 54, pp. 68 144, Vol. 8 Receptor	4-Piperidinthesis and rpromidir nonistisch ne H1/H2 otent ago 14-694, 197, pp. 56 Subtype	nyl, 34, and Hista ne, 32, p e, Vol. 3 recepto nists, Vo 999. 9-578, s, Vol. 3	pp mine, p 327, or ol 27, 1986.	
# (. # (.)	AV AW AX AY AZ BA	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. (1963-1970, 1989. Schulze, Arch. Pharm pp. 455-462, 1994 Schulze, European Jantagonists, Vol 6, pp. van der Goot, Eur J. pp. 511-517, 1992. Walczynski, II Farmar Brown, Br. J. Pharma West, Molecular Pharpp. 610-613, 1990. Clapham, Brit. J. Pha 110, pp. Abs. 65P, 00	Medicinal (00) pp. 113 m. 1991, N ledicinal Cl (13-2018, 1 Chem. 1989 n. (Weinher ournal of Po. 177-186, Med. Chem. Co, Non-immacology, rm. Suppl. (1903, 1993.	Chemistry , (Partial) 39-1149. ew 1-(Heterocyclylate 1996. 9, Synthesis and in im), Synthese und knamaceutical Scientings. 1998. 1. , Isothiourea analyclogical studies will dentification of Two	-1163.) Agonist/Antagolist/Antag	nanilido)- thers: Syr clogy of A //H2-antag d histamir mine as po 54, pp. 68 044, Vol. 8 Receptor	4-Piperidinthesis and appropriate the H1/H2 otent ago 14-694, 19 7, pp. 56 Subtype:	nyl, 34, nd Hista ne, 32, p e, Vol. 3 recepto nists, Vo 999. 9-578, 5 s, Vol. 3	pp mine, p 327, or ol 27, 1986. 8,	
けい けい けい けい けい けい けい けい けい けい けい けい けい け	AV AW AX AY AZ BA BB	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. 0 1963-1970, 1989. Schulze, Arch. Pharm pp. 455-462, 1994 Schulze, European J. antagonists, Vol 6, pp. van der Goot, Eur J. pp. 511-517, 1992. Walczynski, II Farma Brown, Br. J. Pharma West, Molecular Pharpp. 610-613, 1990. Clapham, Brit. J. Pha 110, pp. Abs. 65P, 00 Yokoyama, European 1993.	Medicinal (00) pp. 113 m. 1991, N ledicinal Cl 013-2018, 1 Chem. 1989 n. (Weinhe ournal of P o. 177-186, Med. Chen co, Non-im mc., Pharm macology, rm. Suppl. 0/00, 1993.	Chemistry , (Partial) 39-1149. ew 1-(Heterocyclylate 1-(Heterocyclylate) 1-(Heterocycl	-1163.) Agonist/Antagolist/Antag	nanilido)- ithers: Syr clogy of A //H2-antag d histamir mine as po 54, pp. 68 044, Vol. 8 Receptor H3 Rece	4-Piperidi nthesis and rpromidir conistisch ne H1/H2 otent ago 14-694, 19 17, pp. 56 Subtype: ptor Anta	nyl, 34, nd Hista ne, 32, p e, Vol. 3 recepto nists, Vo 999. 9-578, s, Vol. 3 gonist, V	pp imine, p 327, or ol 27, 1986. 8, Vol.	
# L.	AV AV AW AX AY AZ BA BB	Sasse, Bioorganic & Diarylalkyl, Vol 8 (20) Bagley, J. Med. Cher 827-941. Huls, Bioorganic & M Vol. 6, No. 16, pp. 20 Buschauer, J. Med. C 1963-1970, 1989. Schulze, Arch. Pharm pp. 455-462, 1994 Schulze, European J. antagonists, Vol 6, pp. van der Goot, Eur J. pp. 511-517, 1992. Walczynski, II Farmar West, Molecular Pharma West, Molecular Pharma pp. 610-613, 1990. Clapham, Brit. J. Pha 110, pp. Abs. 65P, 00 Yokoyama, European	Medicinal (00) pp. 113 m. 1991, N ledicinal Cl 013-2018, 1 Chem. 1989 n. (Weinhe ournal of P o. 177-186, Med. Chen co, Non-im mc., Pharm macology, rm. Suppl. 0/00, 1993.	Chemistry , (Partial) 39-1149. ew 1-(Heterocyclylate 1-(Heterocyclylate) 1-(Heterocycl	-1163.) Agonist/Antagolist/Antag	nanilido)- ithers: Syr clogy of A //H2-antag d histamir mine as po 54, pp. 68 044, Vol. 8 Receptor H3 Rece	4-Piperidi nthesis and rpromidir conistisch ne H1/H2 otent ago 14-694, 19 17, pp. 56 Subtype: ptor Anta	nyl, 34, nd Hista ne, 32, p e, Vol. 3 recepto nists, Vo 999. 9-578, s, Vol. 3 gonist, V	pp imine, p 327, or ol 27, 1986. 8, Vol.	

		B 1 D 5
Hic	BE	Lip Histamine Receptor, Pharmacochemistry of H3-Receptors, pp. 57-72, 00/00, 1992.
14-6	BF	Stark European Journal of Pharmaceutical Sciences, New potent Histamine H3-Receptor Vol 3, pp. 95464, 1995
	BG	A CONTRACTOR OF THE CONTRACTOR
	T	72
<u></u>		F. C/1
		75 CB VA
ļ		
		CENT On
EXAMINE	R	Afry Sin DATE CONSIDERED 3/10/03 160/2000
*EXAMINE through cit applicant.	R: In	itial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line f not in conformance and not considered. Include copy of this form with next communication to

r~

*